INDEX

A
Abstraction, 512–513
Acemannan, in evidence-based wound management, 574
Aggregation, 512–513
AGRICOLA, 436
Allantoin, in evidence-based wound management, 574
Aloe vera, in evidence-based wound management, 573
Analgesic(s), for feline idiopathic cystitis, 540–541
Anemia, hemolytic, canine immune-mediated, thromboembolic therapy for, 600
Antibiotic(s). See Antimicrobial agents.
Anti-inflammatory agents, for feline idiopathic cystitis, 540–541
Antimicrobial agents for feline idiopathic cystitis, 543
topical, in enhancement of granulation and epithelialization, 566–567
Antiplatelet drugs, overview of, 580–581
Arterial thromboembolism, in small animals, maintenance therapy for, 589–591

B
Bacitracin zinc, in enhancement of granulation and epithelialization, 566
Bayes’ rule, 517
Burn(s), thromboembolic prophylactic therapy for, 595

C
CAB Direct, 434–435
Calcium alginate dressings, 571
Calcium oxalate urolithiasis, treatment of, 548–554
nutritional management in, 548–551
potassium citrate in, 551
thiazide diuretics in, 551–552
vitamin B<sub>6</sub> in, 552
vitamin C in, 552–554
Cancer, thromboembolic prophylactic therapies for, 596
Canine immune-mediated hemolytic anemia, thromboembolic therapy for, 600
Cat(s) lower urinary tract disease in, evidence-based management of, 533–558.
See also Feline lower urinary tract disease (FLUTD), evidence-based management of
thromboembolic therapies in, evidence-based approach to, 579–609. See also Thromboembolic therapies, in dogs and cats, evidence-based approach to.
CDDSS. See Clinical diagnostic decision support system (CDDSS).
Chitosan, in evidence-based wound management, 571
Clinical diagnostic decision support system (CDDSS)
critical appraisal of, 513–519
introduction to, 513–514
pattern recognition methods in, 514–517
questions regarding, 518–519
Clinical reasoning checklist for, 513
decision analysis and, 499–520. See also Decision analysis.
strategies for, 512–513
Cochrane Database of Systematic Reviews, 434
Compendium on Continuing Education for the Practicing Veterinarian, 434
CONSORT, 490
Critical care patients, thromboembolic prophylactic therapies in, 596
Cystitis, feline idiopathic, 533–543. See also Feline idiopathic cystitis.
Decision analysis clinical reasoning and, 499–520
decision trees in, 500–506
described, 499–500
diagnostic process in, 509–513

Note: Page numbers of article titles are in boldface type.
Decision (continued)
- disadvantages of, 500
- situations requiring, 500
- testing and treating thresholds in, 507–509

Decision trees, 500–506
- analysis of, users’ checklist for, 505–506
- components of, 500–501
- for economic decisions, 504–505
- for therapeutic decision, 504
- helping owners to decide in, 502–503
- missing options in, 502
- obtaining utility values from clients and owners, 503–504
- sensitivity analysis in, 501–502
- solving of, 501
- utilities in, 501

Deductive reasoning, 512

Diagnostic process, 509–513
- clinical reasoning strategies in, 512–513
- described, 510–513
- hypotheticodeductive reasoning in, 509
- pattern recognition in, 512
- ranking in, 510–512
- recall in, 510–512

Diagnostic tests
- accuracy of, critically appraising studies reporting, 489–496
- basic concepts related to, 487–489
- characteristics of, 487–488
- evaluation of, 487–497
- results of, types of, 488–489
- screening vs., 488
- terminology related to, 489
- types of, 488

Diuretic(s), thiazide, for calcium oxalate urolithiasis, 551–552

Dog(s)
- protein-losing nephropathy in, 600
- thromboembolic therapy for, 600
- thromboembolic therapies in, evidence-based approach to, 579–609. See also Thromboembolic therapies, in dogs and cats, evidence-based approach to.

Entrez, 435

Epidermal growth factor (EGF), in evidence-based wound management, 572

Epithelialization, enhancement of, therapeutic agents in, 559–577

Equine amnion dressing, 569–570

Equine Veterinary Journal, 410

Evidence-based health care (EBHC), 410

Evidence-based medicine (EBM), 409–417
- defined, 419
- described, 410–415, 579
- history of, 409–410
- in management of FLUTD, 533–558. See also Feline lower urinary tract disease (FLUTD), evidence-based management of.

Evidence-based medicine Working Group, 409

Evidence-based practice (EBP), 410

Evidence-based veterinary medicine (EBVM), 410
- process of, 420
- statistics and, answers to 21 common statistical questions arising from reading scientific manuscripts, 477–486

Evidence-based wound management, 559–577
acemannan in, 574
allantoin in, 574
aloe vera in, 573
chitosan in, 571
epidermal growth factor in, 572
honey in, 572–573
hydrophilic preparations in, 573
live yeast-cell derivative in, 573
low-intensity laser light in, 572
maltodextrin NF in, 574
methods in, 563–564
multipeptide copper complex in, 574
petrolatum in, 573
pulsed electromagnetic field in, 572
results of, 564–567
sugar in, 572
TGC in, 574
therapeutic agents in enhancement of
granulation and epithelialization, 559–577
topical antimicrobial agents in, 566–567
wound dressings in, 567–567
wound lavage solutions in, 564–566

**G**

Gentamicin sulfate, in enhancement of
granulation and epithelialization, 566
Glycosaminoglycan(s), for feline idiopathic
cystitis, 541–542
Gold standard, defined, 489
Granulation, enhancement of, therapeutic
agents in, 559–577

**H**

Handbook of Evidence-Based Veterinary Medicine,
410
Hemolytic anemia, canine immune-mediated,
thromboembolic therapy for, 600
Heparin, overview of, 581–582
Honey, in evidence-based wound
management, 572–573
Hydrocolloid occlusive dressings, 567
Hydrogel, 568
Hydrolized bovine collagen dressings,
570–571
Hydrophilic preparations, in evidence-based
wound management, 573
Hyperadrenocorticinism, in dogs and cats,
thromboembolic therapy for, 600
Hypotheticodeductive reasoning, in decision
analysis, 509

**I**

Idiopathic cystitis, feline, 535–543. See also
**Feline idiopathic cystitis.**
In Practice, 434
Inductive reasoning, 512
International Veterinary Information Service
(IVIS), 436
IVIS. See International Veterinary Information
Service (IVIS).

**J**

Journal of Equine Veterinary Science, 410

**L**

Laser light, low-intensity, in evidence-based
wound management, 572
Likelihood ratio, defined, 489
Likelihood ratio negative (LR−), defined, 489
Likelihood ratio positive (LR+), defined, 489
List matching, in pattern recognition,
514–517
Live yeast-cell derivative, in evidence-based
wound management, 573

**F**

Feline aortic thromboembolism,
thromboembolic therapy for, 599–600
Feline facial pheromone therapy, for feline
idiopathic cystitis, 541
Feline idiopathic cystitis, 535–543
analgesics in, 540–541
anti-inflammatory agents in, 540–541
antimicrobials for, 543
described, 535–536
environmental enrichment and stress
reduction in, 536–537
feline facial pheromone therapy in, 541
fluid therapy for, 542
glycosaminoglycans in, 541–542
nutritional management in,
537–540
propantheline for, 542–543
Feline lower urinary tract disease (FLUTD)
described, 533
evidence-based management of,
533–558
application of, 534–535
calcium oxalate urolithiasis, 548–554
struvite urolithiasis, 543–548
feline idiopathic cystitis, 535–543
prevalence of, 533–534
Fluid therapy, for feline idiopathic cystitis,
542
FLUTD. See Feline lower urinary tract disease
(FLUTD).
Logic, in pattern recognition, 514
Lower urinary tract disease, in cats, evidence-based management of, 533–558. See also *Feline lower urinary tract disease (FLUTD), evidence-based management of.*
Low-intensity laser light, in evidence-based wound management, 572

**M**
Maltodextrin NF, in evidence-based wound management, 574
MEDLINE, 409, 435
Multipepptide copper complex, in evidence-based wound management, 574

**N**
National Center for Biotechnology Information (NCBI), 435
NCBI. See National Center for Biotechnology Information (NCBI).
Negative predictive value (NPV), defined, 489
Neomycin sulfate, in enhancement of granulation and epithelialization, 566
Nephropathy(ies), protein-losing, in dogs, thromboembolic therapy for, 600
Nonadherent dressings, 569
NPV. See Negative predictive value (NPV).
Nutrition in calcium oxalate urolithiasis management, 548–551
in feline idiopathic cystitis, 537–540

**Q**
OLDMEDLINE, 435
*Online Mendelian Inheritance in Animals*, 435
Orthopedic(s), thromboembolic prophylactic therapy in, 595

**P**
Pattern recognition, in diagnostic process, 512
Petrolatum, in evidence-based wound management, 573
Polyethylene semiocclusive dressings, 567–568
Polymyxin B sulfate, in enhancement of granulation and epithelialization, 566
Polyurethane foam, 569
Porcine small intestinal submucosa (PSIS) dressing, 570
Positive predictive value (PPV), defined, 489
Potassium citrate, for calcium oxalate urolithiasis, 551
PPV. See Positive predictive value (PPV).
Probabilities, in pattern recognition, 517
Propantheline, for feline idiopathic cystitis, 542–543
Protein-losing enteropathy, in dogs and cats, thromboembolic therapy for, 600
Protein-losing nephropathy, in dogs, thromboembolic therapy for, 600
PSIS dressing. See Porcine small intestinal submucosa (PSIS) dressing.
PubMed, 435
*PubMed Central*, 435
Pulmonary thromboembolism, in small animals, maintenance therapy for, 583
Pulsed electromagnetic field, in evidence-based wound management, 572

**R**
Ranking, in diagnostic process, 510–512
Reasoning deductive, 512
hypotheticodeductive, in decision analysis, 509
inductive, 512
Recall, in diagnostic process, 510–512
Research networks, practice-based, 530
Research papers, in evaluation of evidence, 449–450
Research studies, in evaluation of evidence, 451–460
case-control studies, 455–456
cohort studies, 453–455
cross-over designs, 452–453
cross-sectional surveys, 457
diagnostic tests and screening tests, 457–458
poorly controlled or uncontrolled trials, 458–459
qualitative research, surveys, case reports, and case series, 459–460
randomized controlled trials, 451–452
Research synthesis, in evaluation of evidence, 450–451

**S**
Screening, diagnostic tests vs., 488
Sensitivity, defined, 489
Sensitivity analysis, decision trees and, 501–502
Silver sulfadiazine, in enhancement of granulation and epithelialization, 566–567
Soft tissue injuries, thromboembolic prophylactic therapy for, 595–596
Specificity, defined, 489
Spinal cord injuries, thromboembolic prophylactic therapy in, 595
Struvite urolithiasis
  recurrence of, prevention of, 547–548
  treatment of, 543–548
  evidence related to, 546–547
  recommendations in, 546
  urethral plugs in, 547–548
Sugar, in evidence-based wound management, 572

T
  Taxonomy Database, 435
TCC. See Tripeptide copper complex (TCC).
  The Veterinary Record, 410
Thiazide diuretics, for calcium oxalate urolithiasis, 551–552
Threshold(s), testing and treating, in decision analysis, 507–509
Thromboembolic therapies
described, 579–580
in dogs and cats, 586–587
  evidence-based approach to, 579–609
  antiplatelet drugs, overview of, 580–581
  heparin, overview of, 581–582
  in canine immune-mediated hemolytic anemia, 600
  in feline aortic thromboembolism, 599–600
  in hyperadrenocorticism, 600
  in protein-losing enteropathy, 600
  in protein-losing nephropathy, 600
  in surgical patients, 600
  vitamin K antagonists, overview of, 583
  maintenance therapies, 589–593
  prophylactic therapy, 597–599
  recommendations for, 587
  in humans, 583–586
    maintenance therapies, 587–589
    prophylactic therapy, 597–599
    in burn victims, 595
    in cancer patients, 596
    in critical care patients, 596
    in general soft tissue surgery, 593–594
    in medical conditions, 595–596
    in orthopedic surgery, 595
    in spinal cord injury, 595
    in trauma patients, 595
    in small animals, 586–587, 589–593
  overview of, 580
Thromboembolism
  arterial, in small animals, maintenance therapy for, 589–591
  pulmonary, in small animals, maintenance therapy for, 583
Trauma, thromboembolic prophylactic therapy in, 595
Tripeptide copper complex (TCC), in evidence-based wound management, 574

U
Urethral plugs, in prevention of struvite urolithiasis, 547–548
Urolithiasis
calcium oxalate, 548–554. See Calcium oxalate urolithiasis.
  struvite, 543–548. See also Struvite urolithiasis.
US National Agriculture Library, 436

V
Veterinary evidence
critical appraisal of, in scientific literature, small animal clinician’s guide to, 463–475
  evaluation of statistical evidence in, 472–474
  study design considerations in, 465–472
  study population in, 464–465
  evaluation of, 447–462
  primary research studies in, 451–460. See also Research studies, in evaluation of evidence.
  ranking evidence in, 449
  research papers in, 449–450
  research synthesis in, 450–451
  scientific evidence, 449
  searching for, 433–445
Veterinary information, locating and acquiring of
Veterinary (continued)
  heuristics in, 436–442
  libraries in, 443–444
  mechanics for locating, 436–442
  PDAs in, 443–444
  RSS feeds in, 443–444
  search strategies in, 436–442
Veterinary Information Network (VIN), 436, 568
Veterinary information resources
  AGRICOLA, 436
  CAB Direct, 434–435
  consultant, 436
  IVIS, 436
  overview of, 433–436
  PubMed, 435
  VIN, 436
Veterinary medicine
  evolution of, 415–416
  revolution in, 416
Veterinary practice, repackaging of, 416
VIN. See Veterinary Information Network (VIN).
Vitamin(s)
  B₆, for calcium oxalate urolithiasis, 552
  C, for calcium oxalate urolithiasis, 552–554
Vitamin K antagonists, overview of, 583

W
Wound dressings, 567–571
  calcium alginate dressings, 571
  equine amnion dressing, 569–570
  hydrocolloid occlusive dressings, 567
  hydrogel, 568
  hydrolized bovine collagen dressings, 570–571
  nonadherent dressings, 569
  polyethylene semiocclusive dressings, 567–568
  polyurethane foam, 569
  PSIS dressing, 570
Wound healing, stages of, 559–560
Wound lavage solutions, in enhancement of granulation and epithelialization, 564–566
Wound management, evidence-based, 559–577. See also Evidence-based wound management.

Y
Yeast-cell derivative, live, in evidence-based wound management, 573

Z
Zinc, bacitracin, in enhancement of granulation and epithelialization, 566